Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
78 participants
INTERVENTIONAL
2016-03-31
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MR-based Hypofractionated Adaptive IGRT of Prostate Cancer (M-base HyPro 2.0)
NCT03880851
Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
NCT02470910
MR Image Guided Therapy in Prostate Cancer
NCT01377753
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
NCT05676463
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
NCT03160794
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary endpoint: Grade 2+ GI (gastrointestinal) and genitourinary (GU) toxicity after 2 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Radiation
IGRT 5x 2Gy/week, total dose: 78 Gy
IGRT
MR-based IGRT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IGRT
MR-based IGRT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* indication for curative treatment
* ECOG performance scale 0-2
* Informed consent
Exclusion Criteria
* age\<18year
* previous pelvic radiotherapy or prostatic treatment like TURP (transurethral resection of prostate), HIFU (high intensity focused ultrasound)
* serious comorbidity leading to inability for IGRT (image-guided radiotherapy)
* contraindications for MRI (Magnetic Resonance Imaging)
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arndt-Christian Mueller
PD Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arndt-Christian Müller, Dr.
Role: PRINCIPAL_INVESTIGATOR
Department of Radiation Oncology, University of Tübingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Müller Arndt-Christian
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M-base Pro 1.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.